Literature DB >> 14634007

Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor.

Yong Wang1, René Coulombe, Dale R Cameron, Louise Thauvette, Marie-Josée Massariol, Lynn M Amon, Dominique Fink, Steve Titolo, Ewald Welchner, Christiane Yoakim, Jacques Archambault, Peter W White.   

Abstract

Interaction between the E2 protein and E1 helicase of human papillomaviruses (HPVs) is essential for the initiation of viral DNA replication. We recently described a series of small molecules that bind to the N-terminal transactivation domain (TAD) of HPV type 11 E2 and inhibits its interaction with E1 in vitro and in cellular assays. Here we report the crystal structures of both the HPV11 TAD and of a complex between this domain and an inhibitor, at 2.5- and 2.4-A resolution, respectively. The HPV11 TAD structure is very similar to that of the analogous domain of HPV16. Inhibitor binding caused no significant alteration of the protein backbone, but movements of several amino acid side chains at the binding site, in particular those of Tyr-19, His-32, Leu-94, and Glu-100, resulted in the formation of a deep hydrophobic pocket that accommodates the indandione moiety of the inhibitor. Mutational analysis provides functional evidence for specific interactions between Tyr-19 and E1 and between His-32 and the inhibitor. A second inhibitor molecule is also present at the binding pocket. Although evidence is presented that this second molecule makes only weak interactions with the protein and is likely an artifact of crystallization, its presence defines additional regions of the binding pocket that could be exploited to design more potent inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634007     DOI: 10.1074/jbc.M311376200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2.

Authors:  Eric A Abbate; James M Berger; Michael R Botchan
Journal:  Genes Dev       Date:  2004-08-02       Impact factor: 11.361

Review 2.  Replication and partitioning of papillomavirus genomes.

Authors:  Alison A McBride
Journal:  Adv Virus Res       Date:  2008       Impact factor: 9.937

3.  Dimerization of the papillomavirus E2 protein is required for efficient mitotic chromosome association and Brd4 binding.

Authors:  Juan Cardenas-Mora; Jonathan E Spindler; Moon Kyoo Jang; Alison A McBride
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

4.  Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486.

Authors:  Peter W White; Anne-Marie Faucher; Marie-Josée Massariol; Ewald Welchner; Jean Rancourt; Mireille Cartier; Jacques Archambault
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Structural conservation of druggable hot spots in protein-protein interfaces.

Authors:  Dima Kozakov; David R Hall; Gwo-Yu Chuang; Regina Cencic; Ryan Brenke; Laurie E Grove; Dmitri Beglov; Jerry Pelletier; Adrian Whitty; Sandor Vajda
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

Review 6.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

Authors:  Michelle R Arkin; Yinyan Tang; James A Wells
Journal:  Chem Biol       Date:  2014-09-18

7.  The mitotic chromosome binding activity of the papillomavirus E2 protein correlates with interaction with the cellular chromosomal protein, Brd4.

Authors:  Michael K Baxter; Maria G McPhillips; Keiko Ozato; Alison A McBride
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  Discovering protein-ligand chalcogen bonding in the protein data bank using endocyclic sulfur-containing heterocycles as ligand search subsets.

Authors:  Miguel O Mitchell
Journal:  J Mol Model       Date:  2017-09-24       Impact factor: 1.810

9.  Genetic analysis of the E2 transactivation domain dimerization interface from bovine papillomavirus type 1.

Authors:  David Gagnon; Hélène Sénéchal; Claudia M D'Abramo; Jennifer Alvarez; Alison A McBride; Jacques Archambault
Journal:  Virology       Date:  2013-03-11       Impact factor: 3.616

Review 10.  Targeting human papillomavirus genome replication for antiviral drug discovery.

Authors:  Jacques Archambault; Thomas Melendy
Journal:  Antivir Ther       Date:  2013-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.